Views Expressed Disclaimer:

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.

Financial Highlights – Croda International Plc (LSE: CRDA) – FY2025 Highlights & FY2026 Outlook

  • Group sales up 6.60% at constant currency; Q4 sales increased 5.00%.
  • Consumer Care +8.00%, led by F&F +15.00%; Beauty Actives +6.00%; Life Sciences +8.00%; Industrial Specialties -2.00%.
  • Adjusted operating profit +7.90% with margin improving to 40% (vs 17.20%).
  • Adjusted PBT rose 8.40% to £276.20m; IFRS operating profit impacted by impairment charges.
  • Free cash flow at £161.60m; leverage reduced to 30x; dividend increased to 111p.
  • Transformation programme delivered £28.00m benefits in 2025; targeting ~£100.00m annualised benefits by FY28.
  • New FY28 framework: 3–6% organic CAGR, margin above 00%, FCF-to-sales above 12.00%, ROIC above 10.00%.
  • FY2026 outlook: Sales growth within 3–6% range; operating profit expected in line with market expectations at constant currency.

Croda International Plc (LSE: CRDA)

Croda International Plc (LSE: CRDA) moved higher on 24 February 2026 following a constructive business update. The UK-based specialty chemicals manufacturer, serving Consumer Care, Life Sciences and Industrial markets, outlined improved operational discipline and a refined innovation framework. The update referenced enhanced customer engagement, a more favourable product mix in premium categories, and continued progress under its transformation programme. Management reiterated confidence in its medium-term growth pathway, supported by efficiency measures and a disciplined approach to capital allocation.

Croda International Plc (LSE: CRDA) Advances as Consumer Care and Life Sciences Drive Steady Progress

Croda International Plc (LSE: CRDA) hares moved higher in European trading after the specialty chemicals group reported improved momentum across its Consumer Care and Life Sciences divisions. The update reflected progress in margins and operational execution, supported by its differentiated portfolio. Management outlined a structured plan focused on consistent organic growth, enhanced profitability, and improved returns, alongside optimisation of research and development resources. The company also introduced a multi-year financial framework aimed at strengthening performance across key global markets.

Technical View: Croda International Plc (LSE: CRDA) Surges Above 50-Day SMA — Is Momentum Building for Further Upside?

From a technical perspective, Croda International Plc (LSE: CARD) is trading near GBX 3,212.00, advancing 7.60%, and firmly positioned above its 50-day SMA at GBX 2,823.18, which continues to provide dynamic support. The recent breakout reflects a sharp improvement in price structure, with higher highs emerging after a prolonged consolidation phase. The RSI (14) stands at 68.84, indicating strengthening momentum as it approaches elevated territory. Immediate support is placed near GBX 2,950.00, followed by GBX 2,800.00, while the next upside zone is seen around GBX 3,550.00–3,750.00.

Bottom Line: Croda’s Re-Rating Backed by Strategy and Margin Focus

Croda International PLC (LSE: CARD) recent advance reflects improving sales momentum, margin progression, and disciplined execution. With a clearer medium-term framework and focus on innovation-led growth and efficiency gains, the broader outlook remains constructive, although near-term consolidation may follow the sharp move.